Fire Pitch of the Week: Lindis Blood Care | Powered by SeedBlink

In clinical studies CATUVAB® has shown to be effective and safe removing cancer cells from 14 major tumor indications reliably from salvaged blood during cancer surgeries. CE certification ongoing, expected for Q4 2024. FDA submission planned for Q3 2024. In the meantime received letters of intent from several hospitals and hospital groups which would like to use CATUVAB® in their clinical routine.
00:30 - Introduction & overview
02:40 - Garage story
07:00 - The problem & the solution
07:20 - Business model
09:30 - Current traction & key milestones
11:30 - Team presentation
13:00 - Future events
16:10 - Addressable market & competitive landscape
17:00 - Use of funds & financial roadmap
19:00 - Final investment terms